表紙:in silico臨床試験の市場予測・競合動向・成長機会 (~2026年):産業・治療領域・地域別
市場調査レポート
商品コード
1025689

in silico臨床試験の市場予測・競合動向・成長機会 (~2026年):産業・治療領域・地域別

Global In Silico Clinical Trials Market, By Industry, By Therapeutic Area, By Region, Competition Forecast & Opportunities, 2026

出版日: | 発行: TechSci Research | ページ情報: 英文 112 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.75円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

in silico臨床試験の市場予測・競合動向・成長機会 (~2026年):産業・治療領域・地域別
出版日: 2021年09月01日
発行: TechSci Research
ページ情報: 英文 112 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のin silico臨床試験の市場は、先端医療およびヘルスケア産業の急速な進化によって成長すると予測されています。

動物やヒトを対象とした臨床試験では、有害な影響やリソースの枯渇などの批判にさらされることが多くありましたが、in silico臨床試験は、それらの欠点を克服した、より優れた方法と考えられています。in silico臨床試験は、時間と資源を節約し、倫理的な問題を管理することができるため、好んで利用されており、市場成長を支える結果となっています。

当レポートでは、世界のin silico臨床試験の市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、顧客の声の分析、市場規模の推移・予測、産業・治療領域別の内訳、地域・主要国別の詳細分析、競合環境、市場シェア、主要企業のプロファイルなどをまとめています。

目次

第1章 製品の概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19の影響

第5章 顧客の声

第6章 世界市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • 産業別
      • 医療機器
      • 製薬
    • 治療領域別
      • 腫瘍
      • 感染症
      • 血液
      • 心臓病
      • 皮膚科
      • 神経
      • 糖尿病
      • その他
    • 企業別
    • 地域別
  • 製品市場マップ

第7章 北米市場の分析・予測

  • 市場規模・予測
  • 市場シェア・予測
    • 産業別
    • 治療領域別
    • 国別

第8章 欧州市場の分析・予測

  • 市場規模・予測
  • 市場シェア・予測
    • 産業別
    • 治療領域別
    • 国別

第9章 アジア太平洋市場の分析・予測

  • 市場規模・予測
  • 市場シェア・予測
    • 産業別
    • 治療領域別
    • 国別

第10章 南米市場の分析・予測

  • 市場規模・予測
  • 市場シェア・予測
    • 産業別
    • 治療領域別
    • 国別

第11章 中東・アフリカ市場の分析・予測

  • 市場規模・予測
  • 市場シェア・予測
    • 産業別
    • 治療領域別
    • 国別

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向

第14章 競合情勢

  • 競合の見通し
  • 企業プロファイル
    • Certara, Inc.
    • Novadiscovery Sas
    • Insilico Medicine, Inc.
    • Dassault Systemes SE
    • GNS Healthcare Inc
    • The AnyLogic Company
    • InSilicoTrials
    • Immunetrics Inc
    • Nuventra Pharma Sciences
    • Abzena Ltd

第15章 戦略的提言

第16章 当社について&免責事項

目次
Product Code: 7739

The growth of global in silico clinical trials market in the forecast period, 2022-2026 can be attributed to rapidly evolving advanced medicine and healthcare sector. The clinical trials that were conducted on animals and humans often faced criticism for the harmful effects and depleting conditions that arise due to the trials on humans and animals. In silico clinical trials are overcomes the disadvantages of them and are considered a better method. The in silico clinical trials saves time, resources, and manages the ethical issues and are thus preferred, thereby substantiating the growth of the global in silico clinical trials market. This method is financially affordable. The cost of any adverse effect of the trial over humans, is nullified since the in silico clinical trial does not include and human test subjects. Moreover, rapidly increasing concerns over animal welfare and consistent efforts of human and animal rights and welfare organizations is driving the growth of the global in silico clinical trials market in the next five years. Furthermore, in silico clinical trials are readily approved and authorized by the food and drug administration (FDA) and thus substantiate the growth of the market in the future five years. Also, increasing concerns has rendered a lack human and animal test subjects for the participation in the clinical trials. This method is actively influencing the growth of the market in the forecast years until 2026.

In silico clinical trials are computer simulation method for the developmental and regulatory evaluation of the pharmaceutical or medical devices or therapies. The method is not completely evolved currently but a constant research and development affair would benefit the future advancement and drug discovery. The trial is often understood by the involvement of computer system to restructure a 3D image of the organs and systems and then applying the trial methods.

The global in silico clinical trials market segmented is based on industry, therapeutic area, competitional landscape, and regional distribution. Based on industry, the market is further divided between medical devices, and pharmaceuticals. Pharmaceutical sub-segment is anticipated to hold the largest revenue shares of the market and dominate the segment in the upcoming five years, on the account of rapidly increasing instances of drug development and thus conducted clinical trials. Moreover, the concerns over harmful and adverse effects of the newly developed drugs on the animals and human lives being considered as test subject is substantiating the growth of the global in silico clinical trials market in the next five years. Medical devices industry is also benefitting and thus registering significant growth in the future five years on the ground of surging demands for the medically and technologically advanced medical equipment and devices for providing best possible diagnosis and treatment to the population.

Holding the major shares of the global in silico clinical trials market are Certara, Inc., Novadiscovery Sas, Insilico Medicine, Inc., Dassault Systemes SE, GNS Healthcare Inc, The AnyLogic Company, InSilicoTrials, Immunetrics Inc, Nuventra Pharma Sciences, Abzena Ltd, among others. Market players are actively involved in the research and technological development in the advanced medical device and pharmacological developments. The advanced technology has made it possible for the healthcare industry to provide excellent healthcare services through in silico clinical trials. Further advancement would aid the market value and brand establishment in the future five years. New market players may focus on the research and development to provide options that satisfies the consumer demand as well as benefits the market players in building their brand value. Other competitive strategies include mergers & acquisitions and new product developments.

Years considered for this report:

Historical Years: 2016 - 2019

Base Year: 2020

Estimated Year: 2021

Forecast Period: 2022 - 2026

Objective of the Study:

  • To analyze the historical growth of the market size of global in silico clinical trials market from 2016 to 2019.
  • To estimate and forecast the market size of global in silico clinical trials market from 2020 to 2026 and growth rate until 2026.
  • To classify and forecast global in silico clinical trials market based on industry, therapeutic area, competitional landscape, and regional distribution.
  • To identify dominant region or segment in the global in silico clinical trials market.
  • To identify drivers and challenges for global in silico clinical trials market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global in silico clinical trials market.
  • To identify and analyze the profile of leading players operating in global in silico clinical trials market.
  • To identify key sustainable strategies adopted by market players in global in silico clinical trials market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers, suppliers, and distributors across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufactures which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufactures, distribution channels and presence of all major players across the country.

TechSci Research calculated the market size of global in silico clinical trials market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Manufacturers, end users, and other stakeholders
  • Distributors and suppliers of products and other stakeholders
  • Organizations, forums, and alliances related to in silico clinical trials
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global in silico clinical trials market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global In Silico Clinical Trials Market, By Industry:

Medical Devices

Pharmaceutical

  • Global In Silico Clinical Trials Market, By Therapeutic Area:

Oncology

Infectious Disease

Hematology

Cardiology

Dermatology

Neurology

Diabetes

Others

  • Global In Silico Clinical Trials Market, By Region:

North America

  • United States
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Australia

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE

South America

  • Brazil
  • Argentina
  • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global in silico clinical trials market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global In Silico Clinical Trials Market

4. Executive Summary

5. Voice of Customer

  • 5.1. Product/Service Awareness
  • 5.2. Brand Awareness
  • 5.3. Benefits of Switching to In Silico Clinical Trials

6. Global In Silico Clinical Trials Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Industry (Medical Devices v/s Pharmaceutical)
    • 6.2.2. By Therapeutic Area (Oncology, Infectious Disease, Hematology, Cardiology, Dermatology, Neurology, Diabetes, Others)
    • 6.2.3. By Company (2020)
    • 6.2.4. By Region
  • 6.3. Product Market Map

7. North America In Silico Clinical Trials Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Industry
    • 7.2.2. By Therapeutic Area
    • 7.2.3. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States In Silico Clinical Trials Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Industry
        • 7.3.1.2.2. By Therapeutic Area
    • 7.3.2. Mexico In Silico Clinical Trials Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Industry
        • 7.3.2.2.2. By Therapeutic Area
    • 7.3.3. Canada In Silico Clinical Trials Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Industry
        • 7.3.3.2.2. By Therapeutic Area

8. Europe In Silico Clinical Trials Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Industry
    • 8.2.2. By Therapeutic Area
    • 8.2.3. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France In Silico Clinical Trials Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Industry
        • 8.3.1.2.2. By Therapeutic Area
    • 8.3.2. Germany In Silico Clinical Trials Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Industry
        • 8.3.2.2.2. By Therapeutic Area
    • 8.3.3. United Kingdom In Silico Clinical Trials Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Industry
        • 8.3.3.2.2. By Therapeutic Area
    • 8.3.4. Italy In Silico Clinical Trials Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Industry
        • 8.3.4.2.2. By Therapeutic Area
    • 8.3.5. Spain In Silico Clinical Trials Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Industry
        • 8.3.5.2.2. By Therapeutic Area

9. Asia-Pacific In Silico Clinical Trials Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Industry
    • 9.2.2. By Therapeutic Area
    • 9.2.3. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China In Silico Clinical Trials Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Industry
        • 9.3.1.2.2. By Therapeutic Area
    • 9.3.2. India In Silico Clinical Trials Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Industry
        • 9.3.2.2.2. By Therapeutic Area
    • 9.3.3. South Korea In Silico Clinical Trials Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Industry
        • 9.3.3.2.2. By Therapeutic Area
    • 9.3.4. Japan In Silico Clinical Trials Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Industry
        • 9.3.4.2.2. By Therapeutic Area
    • 9.3.5. Australia In Silico Clinical Trials Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Industry
        • 9.3.5.2.2. By Therapeutic Area

10. South America In Silico Clinical Trials Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Industry
    • 10.2.2. By Therapeutic Area
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil In Silico Clinical Trials Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Industry
        • 10.3.1.2.2. By Therapeutic Area
    • 10.3.2. Argentina In Silico Clinical Trials Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Industry
        • 10.3.2.2.2. By Therapeutic Area
    • 10.3.3. Colombia In Silico Clinical Trials Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Industry
        • 10.3.3.2.2. By Therapeutic Area

11. Middle East and Africa In Silico Clinical Trials Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Industry
    • 11.2.2. By Therapeutic Area
    • 11.2.3. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa In Silico Clinical Trials Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Industry
        • 11.3.1.2.2. By Therapeutic Area
    • 11.3.2. Saudi Arabia In Silico Clinical Trials Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Industry
        • 11.3.2.2.2. By Therapeutic Area
    • 11.3.3. UAE In Silico Clinical Trials Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Industry
        • 11.3.3.2.2. By Therapeutic Area

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Competition Outlook
  • 14.2. Company Profiles (SWOT Analysis of Top 5 Players Profiled)
    • 14.2.1. Certara, Inc.
    • 14.2.2. Novadiscovery Sas
    • 14.2.3. Insilico Medicine, Inc.
    • 14.2.4. Dassault Systemes SE
    • 14.2.5. GNS Healthcare Inc
    • 14.2.6. The AnyLogic Company
    • 14.2.7. InSilicoTrials
    • 14.2.8. Immunetrics Inc
    • 14.2.9. Nuventra Pharma Sciences
    • 14.2.10. Abzena Ltd

15. Strategic Recommendations

16. About Us & Disclaimer